RF – New Treatments in Cutaneous Lupus Erythematosus: Current and Future Perspectives

Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous […]

Los resultados de un nuevo estudio indican que la aplicación del fármaco sobre la piel lesionada mejora la histopatología y reduce la activación inmunitaria local.